PolyNucleotide Treatment Protocol

HAUS OF ÄSTHETIK

CROMA PHIART POLYNUCLEOTIDE TREATMENT PROTOCOL (NEXT, EYE, HAIR)

DATE OF IMPLEMENTATION 1ST APRIL 2025

REVIEW DATE 1ST APRIL 2026

VERSION NUMBER 1.1

INTRODUCTION

This protocol outlines the safe, effective, and evidence-based administration of Polynucleotides within the Croma PHIART range: PHIART Next, PHIART Eye, and PHIART Hair. Polynucleotides are biostimulating injectables derived from purified DNA fragments, designed to improve skin regeneration, hydration, and tissue repair. These treatments enhance fibroblast activity, increase collagen and elastin production, and improve microcirculation, making them highly effective for skin rejuvenation, under-eye improvement, and hair restoration.

This protocol ensures full compliance with CQC, Save Face, NICE, GMC, NMC, MHRA, and HAUS OF ÄSTHETIK’s internal policies, including Medicines Management, Infection Control, Record Keeping, Consent, and Patient Safety Policies. Polynucleotide treatments may only be performed by medically trained professionals(Doctors, Dentists, and Registered Nurses) who have undergone accredited Croma Polynucleotide training or have relevant NHS experience in dermatology, plastic surgery, or aesthetic medicine.

 

INDICATIONS FOR TREATMENT

Product	Indications	Primary Treatment Areas
PHIART NEXT	Skin revitalisation, collagen stimulation, dermal hydration, and tissue elasticity enhancement	Face, neck, décolletage, hands, and stretch marks
PHIART EYE	Periorbital rejuvenation, dark circles, under-eye puffiness, and fine lines	Under-eye hollows (tear troughs), periorbital area
PHIART HAIR	Hair loss (androgenic alopecia, stress-induced hair thinning), scalp rejuvenation	Scalp (crown, temples, hairline)

 

BORDERS AND SAFE INJECTION ZONES

PHIART NEXT (General Skin Revitalisation)

   • Treatment Depth: Superficial dermis (intradermal or papillary layer) using microinjections or nappage technique

   • Injection Points: Distributed across the face, neck, and hands in a grid-like pattern

• Borders of Treatment:

   • Avoid midline of the thyroid gland in the neck

   • Stay 5mm away from the vermillion border of the lips

   • Avoid over-injecting in mobile areas such as the nasolabial fold or mental crease

PHIART EYE (Periorbital Rejuvenation)

   • Treatment Depth: Superficial subdermal (0.5mm–1mm depth)

   • Injection Points: Five-point technique or linear threading beneath the tear trough area

• Borders of Treatment:

   • Stay at least 5mm below the lower lash line

   • Avoid injecting directly over the orbital rim

   • Avoid injection into the fat pads (to prevent excessive swelling)

PHIART HAIR (Scalp Rejuvenation & Hair Loss Treatment)

   • Treatment Depth: Intradermal (1mm–1.5mm depth)

   • Injection Points: Linear threading or nappage technique across areas of thinning hair

• Borders of Treatment:

   • Avoid injecting into actively inflamed or infected scalp areas

   • Avoid injecting within 2cm of open hair transplant donor or recipient site

 

PRODUCT STORAGE INFORMATION

   • Polynucleotides must be stored at 2°C–25°C in a secure, temperature-controlled environment

   • Check batch numbers and expiry dates before use

   • Maintain sterility by using single-use syringes and aseptic preparation techniques

 

STAFF REQUIREMENTS

   • Only Doctors, Dentists, and Registered Nurses with documented training in Polynucleotides may administer these treatments

   • Practitioners must hold valid indemnity insurance

   • Non-prescribers must ensure a face-to-face consultation with a prescriber before treatment

 

INCLUSION CRITERIA

Patients must be:

   • Over 18 years old

   • Medically fit with no contraindications

   • Able to provide informed consent

   • Realistic in their treatment expectations

 

EXCLUSION CRITERIA

Polynucleotide treatment is contraindicated in:

   • Patients under 18 (refer to Safeguarding Policy and Children’s Act 2021)

   • Pregnant or breastfeeding individuals

   • Patients with active skin infections, acne, or inflammatory conditions at the injection site

   • History of severe allergic reactions to polynucleotides or DNA-based therapies

   • Autoimmune disorders requiring immunosuppressive therapy

   • Active malignancies or undergoing chemotherapy

   • Blood disorders or patients on anticoagulation therapy (relative contraindication)

 

PRE-TREATMENT ASSESSMENT

Each patient must undergo a comprehensive consultation, including:

   • Full medical history, medication review, and allergy history

   • Analysis of skin type, hydration, and elasticity (for PHIART Next & Eye)

   • Scalp assessment, hair density, and shedding pattern (for PHIART Hair)

   • Pre-treatment photographs for medical documentation

   • Informed consent covering treatment risks, benefits, and expected outcomes

Patients must avoid NSAIDs, alcohol, and blood-thinning medications 48 hours before treatment to minimise the risk of bruising.

 

TREATMENT ADMINISTRATION

General Injection Guidelines

   • Wear sterile gloves and maintain aseptic technique throughout

   • Disinfect the treatment area using chlorhexidine or 70% isopropyl alcohol

   • Use the appropriate needle size (typically 30G or 32G)

   • Use linear threading, nappage, or multiple micro-injections, depending on the area treated

   • Inject slowly and evenly to prevent excessive post-procedural swelling

   • Gently massage the area post-injection to aid distribution

Recommended Dosage Per Session

Product	Injection Volume Per Area	Session Frequency
PHIART NEXT	2–4mL across the face, neck, or hands	Every 3–4 weeks for 3 sessions
PHIART EYE	1mL per eye (0.5mL per side)	Every 2–3 weeks for 3 sessions
PHIART HAIR	2–4mL across the scalp	Every 3–4 weeks for 4 sessions

Results typically improve 4–6 weeks after the final session, with maintenance sessions recommended every 6–9 months.

 

POST-TREATMENT CARE

   • Avoid makeup, saunas, sunbeds, and excessive sun exposure for 48 hours

   • Apply SPF 50 to prevent post-inflammatory hyperpigmentation

   • Avoid strenuous exercise, alcohol, and blood-thinning medications for 24 hours

   • For scalp treatments, avoid washing hair for 24 hours

   • Mild bruising, swelling, and tenderness are normal and should resolve within a few days

Patients should be booked for a follow-up consultation in 4 weeks to assess results and schedule maintenance.

 

MEDICAL RECORD KEEPING

Practitioners must document:

   • Patient identity, medical history, and consent form

   • Product used, batch number, and expiry date

   • Injection sites, volumes, and depth of administration

   • Pre- and post-treatment photographs

   • Any complications or unexpected reactions

Records must comply with GDPR and HAUS OF ÄSTHETIK’s Record Keeping Policy.

 

ADVERSE EVENTS MANAGEMENT

Common side effects include mild redness, swelling, and bruising.

Serious complications requiring immediate escalation include:

   • Infection or abscess formation

   • Delayed-onset inflammatory reactions

   • Excessive swelling or vascular compromise

All severe adverse reactions must be reported to the MHRA Yellow Card Scheme and documented in the clinic’s incident log.

 

QUALITY ASSURANCE AND TRAINING

Practitioners must complete ongoing CPD in Polynucleotide therapy, advanced injection techniques, and complication management. Clinical audits and peer reviews will be conducted to maintain high standards.

This protocol will be reviewed annually or updated based on new clinical evidence or regulatory changes.

 

CONCLUSION

The Croma Polynucleotide Protocol at HAUS OF ÄSTHETIK ensures safe, effective, and ethical administration, providing optimal patient care, safety, and regulatory compliance.